Skip to main content
Top
Published in: Current Bladder Dysfunction Reports 4/2010

Open Access 01-12-2010

Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors

Author: J. Kellogg Parsons

Published in: Current Bladder Dysfunction Reports | Issue 4/2010

Login to get access

Abstract

The epidemiology of benign prostatic hyperplasia (BPH) and male lower urinary tract symptoms (LUTS) has evolved considerably during the past several years. The term LUTS describes a distinct phenotype and allows for a broad epidemiologic description of urinary symptoms at a population level. Although it is becoming the preferred term for studying urinary symptoms in populations, LUTS remains interconnected with BPH in the literature. The incidence and prevalence of BPH and LUTS are increasing rapidly as the US population ages. BPH and LUTS are associated with serious medical morbidities, an increased risk of falls, depression, diminished health-related quality of life, and billions of dollars in annual health care costs. Although age and genetics play important roles in the etiology of BPH and LUTS, recent insights at the population level have revealed that modifiable risk factors are likely key components as well. Serum dihydrotestosterone, obesity, elevated fasting glucose, diabetes, fat and red meat intake, and inflammation increase the risk; vegetables, regular alcohol consumption, exercise, and NSAIDs decrease the risk.
Literature
1.
go back to reference Wei JT, Calhoun E, Jacobsen SJ: Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005, 173:1256–1261.CrossRefPubMed Wei JT, Calhoun E, Jacobsen SJ: Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005, 173:1256–1261.CrossRefPubMed
2.
go back to reference Kupelian V, Wei JT, O’Leary MP, et al.: Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) survey. Arch Intern Med 2006, 166:2381–2387.CrossRefPubMed Kupelian V, Wei JT, O’Leary MP, et al.: Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) survey. Arch Intern Med 2006, 166:2381–2387.CrossRefPubMed
3.
go back to reference Taylor BC, Wilt TJ, Fink HA, et al.: Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology 2006, 68:804–809.CrossRefPubMed Taylor BC, Wilt TJ, Fink HA, et al.: Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology 2006, 68:804–809.CrossRefPubMed
4.
go back to reference Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E: Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology 2008, 72:318–321.CrossRefPubMed Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E: Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology 2008, 72:318–321.CrossRefPubMed
5.
go back to reference Parsons JK, Wilt TJ, Wang PY, et al.; Osteoporotic Fractures in Men Research Group: Progression of lower urinary tract symptoms in older men: a community based study. J Urol 2010, 183:1915–1920.CrossRefPubMed Parsons JK, Wilt TJ, Wang PY, et al.; Osteoporotic Fractures in Men Research Group: Progression of lower urinary tract symptoms in older men: a community based study. J Urol 2010, 183:1915–1920.CrossRefPubMed
6.
go back to reference Jacobsen SJ, Girman CJ, Guess HA, et al.: Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996, 155:595–600.CrossRefPubMed Jacobsen SJ, Girman CJ, Guess HA, et al.: Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996, 155:595–600.CrossRefPubMed
7.
go back to reference Masumori N, Tsukamoto T, Rhodes T, Girman CJ: Natural history of lower urinary tract symptoms in men—result of a longitudinal community-based study in Japan. Urology 2003, 61:956–960.CrossRefPubMed Masumori N, Tsukamoto T, Rhodes T, Girman CJ: Natural history of lower urinary tract symptoms in men—result of a longitudinal community-based study in Japan. Urology 2003, 61:956–960.CrossRefPubMed
8.
go back to reference Sarma AV, McLaughlin JC, Jacobsen SJ, et al.: Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: the Flint Men’s Health study. Urology 2004, 64:959–965.CrossRefPubMed Sarma AV, McLaughlin JC, Jacobsen SJ, et al.: Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: the Flint Men’s Health study. Urology 2004, 64:959–965.CrossRefPubMed
9.
go back to reference Temml C, Brossner C, Schatzl G, et al.: The natural history of lower urinary tract symptoms over five years. Eur Urol 2003, 43:374–380.CrossRefPubMed Temml C, Brossner C, Schatzl G, et al.: The natural history of lower urinary tract symptoms over five years. Eur Urol 2003, 43:374–380.CrossRefPubMed
10.
go back to reference Centers for Disease Control and Prevention: Trends in aging—United States and worldwide. MMWR Morb Mortal Wkly Rep 2003, 52:101–104, 106. Centers for Disease Control and Prevention: Trends in aging—United States and worldwide. MMWR Morb Mortal Wkly Rep 2003, 52:101–104, 106.
11.
go back to reference Parsons JK, Mougey J, Lambert L, et al.: Lower urinary tract symptoms increase the risk of falls in older men. BJU Int 2009, 104:63–68.CrossRefPubMed Parsons JK, Mougey J, Lambert L, et al.: Lower urinary tract symptoms increase the risk of falls in older men. BJU Int 2009, 104:63–68.CrossRefPubMed
12.
go back to reference Engstrom G, Henningsohn L, Walker-Engstrom ML, Leppert J: Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol Nephrol 2006, 40:485–494.CrossRefPubMed Engstrom G, Henningsohn L, Walker-Engstrom ML, Leppert J: Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol Nephrol 2006, 40:485–494.CrossRefPubMed
13.
go back to reference Hu TW, Wagner TH, Bentkover JD, et al.: Estimated economic costs of overactive bladder in the United States. Urology 2003, 61:1123–1128.CrossRefPubMed Hu TW, Wagner TH, Bentkover JD, et al.: Estimated economic costs of overactive bladder in the United States. Urology 2003, 61:1123–1128.CrossRefPubMed
14.
go back to reference Saigal CS, Joyce G: Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005, 173:1309–1313.CrossRefPubMed Saigal CS, Joyce G: Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005, 173:1309–1313.CrossRefPubMed
15.
go back to reference Sanda MG, Beaty TH, Stutzman RE, et al.: Genetic susceptibility of benign prostatic hyperplasia. J Urol 1994, 152:115–119.PubMed Sanda MG, Beaty TH, Stutzman RE, et al.: Genetic susceptibility of benign prostatic hyperplasia. J Urol 1994, 152:115–119.PubMed
16.
go back to reference Pearson JD, Lei HH, Beaty TH, et al.: Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology 2003, 61:781–785.CrossRefPubMed Pearson JD, Lei HH, Beaty TH, et al.: Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology 2003, 61:781–785.CrossRefPubMed
17.
go back to reference Sanda MG, Doehring CB, Binkowitz B, et al.: Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol 1997, 157:876–879.CrossRefPubMed Sanda MG, Doehring CB, Binkowitz B, et al.: Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol 1997, 157:876–879.CrossRefPubMed
18.
go back to reference Rohrmann S, Fallin MD, Page WF, et al.: Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins. Epidemiology 2006, 17:419–427.CrossRefPubMed Rohrmann S, Fallin MD, Page WF, et al.: Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins. Epidemiology 2006, 17:419–427.CrossRefPubMed
19.
go back to reference Partin AW, Page WF, Lee BR, et al.: Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology 1994, 44:646–650.CrossRefPubMed Partin AW, Page WF, Lee BR, et al.: Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology 1994, 44:646–650.CrossRefPubMed
20.
go back to reference Trifiro MD, Parsons JK, Palazzi-Churas K, et al.: Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int 2010, 105:1554–1559.CrossRefPubMed Trifiro MD, Parsons JK, Palazzi-Churas K, et al.: Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int 2010, 105:1554–1559.CrossRefPubMed
21.
go back to reference • Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E: A prospective study of serum dihydrotesterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo study. J Urol 2010 Jul 17 (Epub ahead of print). This cohort study demonstrated that higher concentrations of serum DHT increase the risk of BPH. Serum total and bioavailable testosterone are not associated with BPH risk. • Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E: A prospective study of serum dihydrotesterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo study. J Urol 2010 Jul 17 (Epub ahead of print). This cohort study demonstrated that higher concentrations of serum DHT increase the risk of BPH. Serum total and bioavailable testosterone are not associated with BPH risk.
22.
go back to reference Kristal AR, Schenk JM, Song Y, et al.: Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2008, 168:1416–1424.CrossRefPubMed Kristal AR, Schenk JM, Song Y, et al.: Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2008, 168:1416–1424.CrossRefPubMed
23.
go back to reference Bhasin S, Singh AB, Mac RP, et al.: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003, 24:299–311.PubMed Bhasin S, Singh AB, Mac RP, et al.: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003, 24:299–311.PubMed
24.
go back to reference Amory JK, Wang C, Swerdloff RS, et al.: The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007, 92:1659–1665.CrossRefPubMed Amory JK, Wang C, Swerdloff RS, et al.: The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007, 92:1659–1665.CrossRefPubMed
25.
go back to reference McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398.CrossRefPubMed McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398.CrossRefPubMed
26.
go back to reference Haffner S, Taegtmeyer H: Epidemic obesity and the metabolic syndrome. Circulation 2003, 108:1541–1545.CrossRefPubMed Haffner S, Taegtmeyer H: Epidemic obesity and the metabolic syndrome. Circulation 2003, 108:1541–1545.CrossRefPubMed
27.
go back to reference Meigs JB, Mohr B, Barry MJ, et al.: Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001, 54:935–944.CrossRefPubMed Meigs JB, Mohr B, Barry MJ, et al.: Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001, 54:935–944.CrossRefPubMed
28.
go back to reference Rohrmann S, Smit E, Giovannucci E, Platz EA: Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005, 29:310–316.CrossRef Rohrmann S, Smit E, Giovannucci E, Platz EA: Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005, 29:310–316.CrossRef
29.
go back to reference Joseph MA, Harlow SD, Wei JT, et al.: Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003, 157:906–914.CrossRefPubMed Joseph MA, Harlow SD, Wei JT, et al.: Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003, 157:906–914.CrossRefPubMed
30.
go back to reference Parsons JK, Carter HB, Partin AW, et al.: Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006, 91:2562–2568.CrossRefPubMed Parsons JK, Carter HB, Partin AW, et al.: Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006, 91:2562–2568.CrossRefPubMed
31.
go back to reference Parsons JK: Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 2007, 178:395–401.CrossRefPubMed Parsons JK: Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 2007, 178:395–401.CrossRefPubMed
32.
go back to reference Parsons JK, Sarma AV, McVary K, Wei JT: Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 2009, 182(6 Suppl):S27–S31.CrossRefPubMed Parsons JK, Sarma AV, McVary K, Wei JT: Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 2009, 182(6 Suppl):S27–S31.CrossRefPubMed
33.
go back to reference Kristal AR, Arnold KB, Schenk JM, et al.: Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. J Urol 2007, 177:1395–1400; quiz 591.CrossRefPubMed Kristal AR, Arnold KB, Schenk JM, et al.: Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. J Urol 2007, 177:1395–1400; quiz 591.CrossRefPubMed
34.
go back to reference Sarma AV, Parsons JK, McVary K, Wei JT: Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms—what do we know? J Urol 2009, 182(6 Suppl):S32–S37.CrossRefPubMed Sarma AV, Parsons JK, McVary K, Wei JT: Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms—what do we know? J Urol 2009, 182(6 Suppl):S32–S37.CrossRefPubMed
35.
go back to reference Parsons JK, Bergstrom J, Barrett-Connor E: Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 2008, 101:313–318.CrossRefPubMed Parsons JK, Bergstrom J, Barrett-Connor E: Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 2008, 101:313–318.CrossRefPubMed
36.
go back to reference Gupta A, Gupta S, Pavuk M, Roehrborn CG: Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006, 68:1198–1205.CrossRefPubMed Gupta A, Gupta S, Pavuk M, Roehrborn CG: Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006, 68:1198–1205.CrossRefPubMed
37.
go back to reference Nandeesha H, Koner BC, Dorairajan LN, Sen SK: Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006, 370:89–93.CrossRefPubMed Nandeesha H, Koner BC, Dorairajan LN, Sen SK: Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006, 370:89–93.CrossRefPubMed
38.
go back to reference • Kristal AR, Arnold KB, Schenk JM, et al.: Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2008, 167:925–934. This analysis of the placebo arm of the Prostate Cancer Prevention Trial included several important observations with respect to diet and BPH, namely higher fat and red meat intake increase, while higher vegetable intake and regular alcohol consumption decrease BPH risk. • Kristal AR, Arnold KB, Schenk JM, et al.: Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2008, 167:925–934. This analysis of the placebo arm of the Prostate Cancer Prevention Trial included several important observations with respect to diet and BPH, namely higher fat and red meat intake increase, while higher vegetable intake and regular alcohol consumption decrease BPH risk.
39.
go back to reference Tavani A, Longoni E, Bosetti C, et al.: Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia: a case-control study from Italy. Eur Urol 2006, 50:549–554.CrossRefPubMed Tavani A, Longoni E, Bosetti C, et al.: Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia: a case-control study from Italy. Eur Urol 2006, 50:549–554.CrossRefPubMed
40.
go back to reference Dal Maso L, Zucchetto A, Tavani A, et al.: Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. Int J Cancer 2006, 118:2632–2635.CrossRefPubMed Dal Maso L, Zucchetto A, Tavani A, et al.: Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. Int J Cancer 2006, 118:2632–2635.CrossRefPubMed
41.
go back to reference Parsons JK, Kashefi C: Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol 2008, 53:1228–1235.CrossRefPubMed Parsons JK, Kashefi C: Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol 2008, 53:1228–1235.CrossRefPubMed
42.
go back to reference Parsons JK, Im R: Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol 2009, 182:1463–1468.CrossRefPubMed Parsons JK, Im R: Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol 2009, 182:1463–1468.CrossRefPubMed
43.
go back to reference Furukawa S, Fujita T, Shimabukuro M, et al.: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752–1761.PubMed Furukawa S, Fujita T, Shimabukuro M, et al.: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752–1761.PubMed
44.
go back to reference Nickel JC, Downey J, Young I, Boag S: Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999, 84:976–981.CrossRefPubMed Nickel JC, Downey J, Young I, Boag S: Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999, 84:976–981.CrossRefPubMed
45.
go back to reference Theyer G, Kramer G, Assmann I, et al.: Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992, 66:96–107.PubMed Theyer G, Kramer G, Assmann I, et al.: Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992, 66:96–107.PubMed
46.
go back to reference Anim JT, Udo C, John B: Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem 1998, 100:439–449.PubMed Anim JT, Udo C, John B: Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem 1998, 100:439–449.PubMed
47.
go back to reference Di Silverio F, Gentile V, De Matteis A, et al.: Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003, 43:164–175.CrossRefPubMed Di Silverio F, Gentile V, De Matteis A, et al.: Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003, 43:164–175.CrossRefPubMed
48.
go back to reference Rohrmann S, De Marzo AM, Smit E, et al.: Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005, 62:27–33.CrossRefPubMed Rohrmann S, De Marzo AM, Smit E, et al.: Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005, 62:27–33.CrossRefPubMed
49.
go back to reference Sutcliffe S, Giovannucci E, De Marzo AM, et al.: Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms. Am J Epidemiol 2005, 162:898–906.CrossRefPubMed Sutcliffe S, Giovannucci E, De Marzo AM, et al.: Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms. Am J Epidemiol 2005, 162:898–906.CrossRefPubMed
50.
go back to reference Sutcliffe S, Zenilman JM, Ghanem KG, et al.: Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol 2006, 175:1937–1942.CrossRefPubMed Sutcliffe S, Zenilman JM, Ghanem KG, et al.: Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol 2006, 175:1937–1942.CrossRefPubMed
51.
go back to reference Sutcliffe S, Rohrmann S, Giovannucci E, et al.: Viral infections and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey. J Urol 2007, 178:2181–2185.CrossRefPubMed Sutcliffe S, Rohrmann S, Giovannucci E, et al.: Viral infections and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey. J Urol 2007, 178:2181–2185.CrossRefPubMed
52.
go back to reference St Sauver JL, Jacobson DJ, McGree ME, et al.: Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006, 164:760–768.CrossRefPubMed St Sauver JL, Jacobson DJ, McGree ME, et al.: Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006, 164:760–768.CrossRefPubMed
Metadata
Title
Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors
Author
J. Kellogg Parsons
Publication date
01-12-2010
Publisher
Current Science Inc.
Published in
Current Bladder Dysfunction Reports / Issue 4/2010
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-010-0067-2

Other articles of this Issue 4/2010

Current Bladder Dysfunction Reports 4/2010 Go to the issue